
Marco Ruella MD
Hematologic Oncology
Assistant Professor of Medicine and Scientific Director, Lymphoma Program
Join to View Full Profile
3400 Civic Center BlvdPerelman Center for Advanced Medicine, SPE 8-112Philadelphia, PA 19104
Phone+1 215-746-4880
Dr. Ruella is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Penn MedicinePost-Doctoral Fellowship, 2012 - 2018
- University of TorinoSpecialty in Hematology, Clinical Hematology and Cell Therapy, cum Laude, 2008 - 2012
- University of Torino Faculty of MedicineClass of 2007
Certifications & Licensure
- PA State Medical License 2018 - 2026
Publications & Presentations
PubMed
- CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India.Luca Paruzzo, Marco Ruella
The Lancet. Haematology. 2025-04-01 - Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges.Fabio Luciani, Arman Safavi, Puneeth Guruprasad, Linhui Chen, Marco Ruella
Blood Cancer Discovery. 2025-03-28 - 1 citationsA patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.Danilo Fiore, Luca Vincenzo Cappelli, Liu Zhaoqi, Nikita Kotlov, Maria Sorokina
Cell Reports. Medicine. 2025-03-24
Journal Articles
- Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B CellVijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature
- Genome-Editing Technologies in Adoptive T Cell Immunotherapy for CancerNathan Singh, Marco Ruella, Carl H June, Current Hematologic Malignancy Reports
Abstracts/Posters
- Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution ExperienceMarco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell LymphomasMarco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell EfficacyMarco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Authored Content
- The Quest To Cure CLL: “Remarkable” Results With New StrategySeptember 2023
- Interleukin-18 Secreting Autologous Anti-CD19 CAR T-cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-cell TherapyDecember 2022
Press Mentions
- Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune CellsDecember 29th, 2024
- Keto Diet Metabolite May Power up CAR T Cells to Kill CancerDecember 9th, 2024
- Keto Diet Might Increase Effectiveness of Certain Cancer TreatmentDecember 9th, 2024
- Join now to see all
Grant Support
- MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCERUNIVERSITY OF PENNSYLVANIA2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: